spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

STORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive Officer

Storm Therapeutics

Industry veteran to lead STORM as it transitions into a clinical-stage company with a pipeline of products targeting RNA modifying enzymes


7 September 2022, Cambridge, UK:
STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modification enzymes for oncology and other diseases, today announced the appointment of Dr. Gerald (Jerry) McMahon as President and Chief Executive Officer and Board Director.

Dr. McMahon brings with him more than 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience with a broad disease-area expertise and a specialty in oncology therapeutics. Dr. McMahon has held scientific, pharmaceutical and venture capital positions and has been the CEO or President of multiple biotechnology companies leading novel therapeutic programs from discovery and development to drug approvals for internal and in-licensed products.

Commenting on the appointment, Tim Edwards, Chairman of STORM Therapeutics, said: “The Board is very pleased to welcome Jerry as CEO at a pivotal time of the Company’s growth and advancement in the field of RNA modifying enzymes (RME). As we look to accelerate progress in our pipeline and our discovery platform, and move our first candidate into clinical development, Jerry’s strong track record and wealth of expertise in clinical and public market experience in the US will further drive the evolution of STORM.”

Dr. Jerry McMahon added: “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development. I look forward to guiding STORM through future growth, capitalizing on our world leading RME drug discovery experience, advancing programs into the clinic, and building the pipeline which was recently validated with a significant partner in oncology.”

Dr. McMahon was President and CEO of NASDAQ listed Harpoon Therapeutics, building the Company from early stage through to IPO, follow-on financings, and development collaborations. Prior to that he held numerous roles including President and CEO of Kolltan Pharmaceuticals which was acquired by Celldex, Senior VP Oncology at Medimmune (AstraZeneca), and President at SUGEN (Pharmacia and Pfizer), where he was instrumental in the invention and full development of several ground-breaking protein kinase inhibitors including sunitinib (Sutent®) marketed by Pfizer. Dr. McMahon has also held academic appointments at the Yale Comprehensive Cancer Center at Yale University, Tufts University School of Medicine, and the Massachusetts Institute of Technology. He received his BS in biology and PhD in the field of biochemistry and genetics from Rensselaer Polytechnic Institute, has authored over 100 scientific and medical publications and is an inventor on over 60 US patents.
phone +44 (0)1223 804174
email info@stormtherapeutics.com
web www.stormtherapeutics.com/
email Babraham Hall House, Babraham, Cambridge CB22 3AT
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Etihad Cargo Achieves IATA CEIV Pharma Recertification for Pharmaceutical Logistics

Abu Dhabi, United Arab Emirates – Etihad Cargo, the cargo and logistics arm of Etihad Aviation Group, has been awarded Center of Excellence for Independent Validators (CEIV) Pharma recertification by the International Air Transport Association (IATA). The carrier is one of only 37 airlines to hold IATA CEIV Pharma certification globally.
More info >>


White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement